Diabetes Insight (audio)Volume 01, Issue 15 November 6, 2010
Kendall D, Bakris G, Bergenstal R, Molitch M, Sowers J, Tuttle K, Vokes T, Wylie-Rosett J. Cardiorenal Issues. Diabetes Insight 1,November 2010.
The link contains an abstracted summary, not a verbatim transcript, of the lectures/discussions on this audio program.
Background
Evidence from individual trials comparing Mediterranean to low-fat diets to modify cardiovascular risk factors remains preliminary.
Maldanado AQ, Davies NM, Crow SA, Little C, Ojogho ON, Weeks DL. Effects of plasmaphoresis on mycophenolic acid concentrations. Transplantation 91:e3-e4, 2011.
December 2010 - Volume 53 - Issue 12 - pp 1604-1610
Lehur, Paul-Antoine M.D., Ph.D.; McNevin, Shane M.D.; Buntzen, Steen M.D., Ph.D.; Mellgren, Anders F. M.D., Ph.D.; Laurberg, Soeren M.D., Ph.D.; Madoff, Robert D. M.D.
Podium Abstract Presentation for the American Society of Colon and Rectal Surgeons 2010.
S.Buntzen,P.Lehur, S. McNevin, A. Mellgren, S. Laurberg, R. Madoff.
Purpose: Restoration of adequate sphincter function in case of end-stage fecal incontinence (FI) is still a challenge. We report our initial clinical results following implantation of a novel magnetic anal sphincter (MAS).
Read more on line (pg 24)
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD), and one of the most prevalent microvascular complications of both type 1 and type 2 diabetes. Additionally, risk of death is increased at all stages of DKD. As early as the microalbuminuric stage, the death rate approaches 20% per year. Therefore, management strategies should address reducing risk of mortality as well as progression to ESRD.
Prevention of Diabetic Kidney Disease: Negative Clinical Trials With Renin-Angiotensin System Inhibitors , Robert G. Nelson, Katherine R. Tuttle. American Journal of Kidney Diseases March 2010 (Vol. 55, Issue 3, Pages 426-430)
The onset of diabetic kidney disease typically is marked by the development of increased urinary albumin excretion. Microalbuminuria, the earliest detectable increase in urinary albumin levels, is defined as an albumin-creatinine ratio in the range of 30-300 mg/g.1 Although there presently is a debate about whether albuminuria is an adequate biomarker of diabetic kidney disease, it remains the test most commonly used by clinicians and researchers alike to screen for diabetic kidney disease. Because angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are proven therapies for diabetic kidney disease characterized by macroalbuminuria (albumin-creatinine ratio > 300 mg/g), by logical extension, these agents might also prevent the development of microalbuminuria. The DIRECT (Diabetic Retinopathy Candesartan Trials)-Renal Program, published in 2009 in the Annals of Internal Medicine,2 and RASS (Renin-Angiotensin System Study), published in 2009 in the New England Journal of Medicine,3 test this hypothesis. (full article on line)
Researchers at Providence Medical Research Center consistently publish in nationally recognized medical journals. The list on the right contains the most recently published articles. Other articles are archived by year published. Full copies of some articles are available on line. If articles are available on line, a link has been provided. For other articles, copies of most journals are available at the Sacred Heart Medical Center Library.
Use the links on the right to view publications.
Handbook of Chronic Kidney Disease Management, John T. Daugirdas. Lippincott Williams & Wilins. Reviewed by Tuttle, KR in Kidney International 80:1008-1009, 2011.
Saha, S.A. Molinar, J. Arora, R.R. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Diabetes, Obesity and Metabolism. Volume 10 Issue 1, Pages 41 - 52
- Options :
- View Article Map